Prospective Grant of an Exclusive Patent License: Predicting Patient Response to Cancer Therapy via Histopathology Images

Краткое содержание

The National Cancer Institute (NCI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Australian National University ("ANU"), a non-profit research institution located in Canberra, Australia for NCI's rights to the patent applications listed in the Supplementary Information section of this notice.